

Electronic Acknowledgement Receipt

EFS ID:	7735364
Application Number:	09993647
International Application Number:	
Confirmation Number:	1010
Title of Invention:	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
First Named Inventor/Applicant Name:	Bernd Riedl
Customer Number:	23599
Filer:	Csaba Henter/Caitlin Sickler
Filer Authorized By:	Csaba Henter
Attorney Docket Number:	BAYER 18A
Receipt Date:	03-JUN-2010
Filing Date:	27-NOV-2001
Time Stamp:	09:51:12
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P159a-Liang-et-al-Blood-v104-Abstract-4446.pdf	182765 <small>78c15d93cf3f7b357d997ec4f7540547da43731b</small>	no	2

Warnings:

Information:

2	NPL Documents	P159b-Li-et-al-Anticancer-Res-v24-n1973.pdf	747081	no	7
			fd4426be9ddb7b359a2bdafd971b996819ae75b9		
Warnings:					
Information:					
3	NPL Documents	P160-LinSynthesisof1-2-Pyridine-1-Oxide.PDF	111793	no	2
			f29cc0940d94352e5b34d4ca02cb27b3e7516ad8		
Warnings:					
Information:					
4	NPL Documents	P160a-Linderholm-et-al-J-Clinical-Oncology-v18-n7-p1423.pdf	547736	no	9
			2786d6d33a88aad66b889d238905bf3a159f5504		
Warnings:					
Information:					
5	NPL Documents	P160b-Linderholm-et-al-Int-J-Cancer-v89-p51.pdf	654177	no	12
			25db814e12972fd1874f97c0176a83359e57dbc		
Warnings:					
Information:					
6	NPL Documents	P160c-LissonietalAntiangiogenic.pdf	571986	no	3
			494d5453776a1acab84a84b2875a413817652873		
Warnings:					
Information:					
7	NPL Documents	P160d-Lissonietalchemotherapy.pdf	892708	no	5
			1e49b78d12607409df2a57d7181a0a9ceea4ccdc4		
Warnings:					
Information:					
8	NPL Documents	P160e-LissonietalAbnorm.pdf	1256913	no	6
			f0263a60d74834dbd9f09fd37deae4c06e97639		
Warnings:					
Information:					
9	NPL Documents	P160f-Lissoni-et-al-Int-J-Biol-Markers-v18-n2-p152.pdf	614473	no	4
			24e80bf915c7d28380cc5a6359ec742490dff3580		
Warnings:					
Information:					
10	NPL Documents	P160h-Lockhart-et-al-Am-J-Clin-Oncology-v29-n2-p109.pdf	670049	no	7
			28574cc5b225452845606186831b3e2300e69e90		
Warnings:					
Information:					

11	NPL Documents	P161-LORIGANETAL-PhaseII Sorafenib Combined.pdf	110074 465a42b6ae6d5ab592c8edeb94f4bb671278aa77	no	2
Warnings:					
Information:					
12	NPL Documents	P162-Lowinger Design and Discovery of Small Molecules Targeting Raf-1 Kinase.pdf	627223 8e6d002b01e201bc26cd7a46bd927b8b8901dad	no	10
Warnings:					
Information:					
13	NPL Documents	P163-Lowinger et al Protein Kinase Inhibitors From The Urea Class.pdf	148446 30e948a99d7bb5597bb1f19ad97857c84f93816c	no	1
Warnings:					
Information:					
14	NPL Documents	P163a-Lowy 1993.pdf	3639523 6fa2f9870b4113fd74783108f4e78f29c2e2e6f	no	41
Warnings:					
Information:					
15	NPL Documents	P164-Ludwig et al MEK Inhibition Impairs Influenza.pdf	815947 38bcec2f3cd57f5a7636b96bb9bbdff308b98731	no	7
Warnings:					
Information:					
16	NPL Documents	P165-LUO0133WO-Enhancement Radiation.pdf	1387325 d357ec6abcce863c1b88076ea8187de08a74c03d	no	12
Warnings:					
Information:					
17	NPL Documents	P166-Lyons Discovery of a Novel Raf Kinase Inhibitor.pdf	816218 8eea8beb1e240da3dce3c172182060977aa09dd3	no	8
Warnings:					
Information:					
18	NPL Documents	P167-Madwed Pharmacological Evaluation of BIRB796.pdf	77971 3c344521d14e8c7195376b0585cdda35d36b3827	no	1
Warnings:					
Information:					
19	NPL Documents	P168-Magnuson et al The Raf-1 Serine-threonine.pdf	635550 30b490dffade334325f7988436caba7a33e7655c	no	7
Warnings:					
Information:					

20	NPL Documents	P160gLLovet2008.pdf	662350 cb2252a0d1f2fae662375b1185c7b11092d ecf6c	no	16
----	---------------	---------------------	--	----	----

Warnings:

Information:

Total Files Size (in bytes):	15170308
-------------------------------------	----------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.